---
schema_version: "secwatch.filing_event.v1"
accession: "0001413329-24-000160"
form_type: "8-K"
ticker: "PM"
cik: "0001413329"
company_name: "Philip Morris International Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:13:53.844528+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMI agrees to sell Vectura Group to Molex for up to GBP 298M; expects ~$220M Q3 loss

## Summary
- Upfront cash consideration of GBP 150M (~$198M) plus up to GBP 148M in contingent milestone payments through 2039.
- Transaction expected to close by end of 2024, subject to regulatory approval and customary closing conditions.
- PMI expects to record an estimated loss of ~$220M in Q3 2024 on the sale, subject to working capital adjustments.
- PMI cites unwarranted opposition to its ownership as reason for sale; remaining Vectura Fertin Pharma units to continue under new identity.
- Vectura will be operated by Phillips Medisize (Molex), focusing on inhalation drug delivery and CDMO services.

## SEC filing metadata
- accession: 0001413329-24-000160
- form_type: 8-K
- ticker: PM
- cik: 0001413329
- company_name: Philip Morris International Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1413329/000141332924000160/0001413329-24-000160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1413329/000141332924000160/pm-20240917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001413329-24-000160
- JSON: https://secwatch.observer/filing/0001413329-24-000160.json
- Plain text: https://secwatch.observer/filing/0001413329-24-000160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.